Download PDF
Horm Metab Res 2013; 45(13): 945-954
DOI: 10.1055/s-0033-1353155
Review
© Georg Thieme Verlag KG Stuttgart · New York

Role of Secretin Peptide Family and their Receptors in the Hypothalamic Control of Energy Homeostasis

R. Sekar
1   School of Biological Sciences; The University of Hong Kong, Pokfulam, Hong Kong
,
B. K. C. Chow
1   School of Biological Sciences; The University of Hong Kong, Pokfulam, Hong Kong
› Author Affiliations
Further Information

Publication History

received 14 May 2013

accepted 13 July 2013

Publication Date:
25 September 2013 (online)

Also available at
    Permissions and Reprints

Abstract

Secretin family of peptide hormones is a group of structurally related brain-gut peptides that exert their functions via interactions with the class B1 G protein-coupled receptors (GPCRs). Recent researches of these peptides and receptors in metabolism have been an area of intense focus for the development of promising drug targets as therapeutic potentials for metabolic disorders. The fact that agonists of GLP-1, a member in the family, have already started being used as therapeutics clearly indicates the importance and relevance of further research on the clinical applications of these peptides. This review aims to provide an overview of the current understanding regarding the importance of this family of peptides as well as their receptors in metabolism with special focus on their actions in the hypothalamus.

Key words

secretin family peptides - energy homeostasis - hypothalamus - secretin family receptors - food intake
 

  • References

  • 1 Cardoso JC, Vieira FA, Gomes AS, Power DM. The serendipitous origin of chordate secretin peptide family members. BMC Evol Biol 2010; 10: 135
    CrossrefPubMedGoogle Scholar
  • 2 Lee VHY, Lee LTO, Chu JYS, Lam IPY, Siu FKY, Vaudry H, Chow BKC. An indispensable role of secretin in mediating the osmoregulatory functions of angiotensin II. FASEB J 2010; 24: 5024-5032
    CrossrefPubMedGoogle Scholar
  • 3 Borle AB. Regulation of cellular calcium metabolism and calcium transport by calcitonin. J Membr Biol 1975; 21: 125-146
    PubMedGoogle Scholar
  • 4 Laburthe M, Couvineau A, Gaudin P, Maorett JJ, Rouyer-Fessard C, Nicole P. Receptors for VIP, PACAP, Secretin, GRF, Glucagon, GLP-1, and Other Members of Their New Family of G Protein-Linked Receptors: Structure-Function Relationship with Special Reference to the Human VIP-1 Receptora. Ann N Y Acad Sci 1996; 805: 94-109
    PubMedGoogle Scholar
  • 5 Harmar AJ. Family-B G-protein-coupled receptors. Genome Biol 2001; 2: reviews 3013.1-reviews 3013.10
    PubMedGoogle Scholar
  • 6 Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol Sci 2011; 32: 591-600
    CrossrefPubMedGoogle Scholar
  • 7 Watkins HA, Au M, Hay DL. The structure of secretin family GPCR peptide ligands: implications for receptor pharmacology and drug development. Drug Discov Today 2012; 17–18: 1006-1014 Erratum in Drug Discov Today 2013; 18: 312–313
    PubMedGoogle Scholar
  • 8 Poyner DR, Hay DL. Secretin family (Class B) G protein-coupled receptors – from molecular to clinical perspectives. Br J Pharmacol 2012; 166: 1-3
    CrossrefPubMedGoogle Scholar
  • 9 Furness SG, Wootten D, Christopoulos A, Sexton PM. Consequences of splice variation on Secretin family G protein-coupled receptor function. Br J Pharmacol 2012; 166: 98-109
    CrossrefPubMedGoogle Scholar
  • 10 de Lecea L, Kilduff T, Peyron C, Gao X-B, Foye P, Danielson P, Fukuhara C, Battenberg E, Gautvik V, Bartlett F. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 1998; 95: 322-327
    CrossrefPubMedGoogle Scholar
  • 11 Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 2004; 10: 1325-1340
    CrossrefPubMedGoogle Scholar
  • 12 Williams G, Bing C, Cai XJ, Harrold JA, King PJ, Liu XH. The hypothalamus and the control of energy homeostasis: different circuits, different purposes. Physiol Behav 2001; 74: 683
    CrossrefPubMedGoogle Scholar
  • 13 Leibowitz SF, Wortley KE. Hypothalamic control of energy balance: different peptides, different functions. Peptides 2004; 25: 473-504
    CrossrefPubMedGoogle Scholar
  • 14 Dietrich MO, Horvath TL. Hypothalamic control of energy balance: insights into the role of synaptic plasticity. Trends Neurosci 2013; 36: 65-73
    CrossrefPubMedGoogle Scholar
  • 15 Morton G, Cummings D, Baskin D, Barsh G, Schwartz M. Central nervous system control of food intake and body weight. Nature 2006; 443: 289-295
    CrossrefPubMedGoogle Scholar
  • 16 Grill HJ, Kaplan JM. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002; 23: 2-40
    CrossrefPubMedGoogle Scholar
  • 17 Lopaschuk GD, Ussher JR, Jaswal JS. Targeting Intermediary Metabolism in the Hypothalamus as a Mechanism to Regulate Appetite. Pharmacol Rev 2010; 62: 237-264
    CrossrefPubMedGoogle Scholar
  • 18 Thorens B. Sensing of glucose in the brain. In: Appetite Control. Joost H-G. (ed.). Springer: Handbook of Experimental Pharmacology; 2012. 209. 277-294
    CrossrefGoogle Scholar
  • 19 Burdakov D, Luckman SM, Verkhratsky A. Glucose-sensing neurons of the hypothalamus. Philos Trans R Soc Lond B Biol Sci 2005; 360: 2227-2235
    PubMedGoogle Scholar
  • 20 Parton LE, Ye CP, Coppari R, Enriori PJ, Choi B, Zhang C-Y, Xu C, Vianna CR, Balthasar N, Lee CE. Glucose sensing by POMC neurons regulates glucose homeostasis and is impaired in obesity. Nature 2007; 449: 228-232
    CrossrefPubMedGoogle Scholar
  • 21 Mounien L, Marty N, Tarussio D, Metref S, Genoux D, Preitner F, Foretz M, Thorens B. Glut2-dependent glucose-sensing controls thermoregulation by enhancing the leptin sensitivity of NPY and POMC neurons. FASEB J 2010; 24: 1747-1758
    CrossrefPubMedGoogle Scholar
  • 22 Lam CK, Chari M, Lam TK. CNS regulation of glucose homeostasis. Physiology 2009; 24: 159-170
    CrossrefPubMedGoogle Scholar
  • 23 Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28: 325-353
    CrossrefPubMedGoogle Scholar
  • 24 Lam IPY, Siu FKY, Chu JYS, Chow BKC. Multiple Actions of Secretin in the Human Body. In: International Review of Cytology. Kwang WJ. (ed.). New York: Academic Press; 2008: 159-190
    Google Scholar
  • 25 Chey WY, Chang T-M. Secretin, 100 years later. J Gastroenterol 2003; 38: 1025-1035
    CrossrefPubMedGoogle Scholar
  • 26 Ng SS, Yung W, Chow BK. Secretin as a neuropeptide. Mol Neurobiol 2002; 26: 97-107
    CrossrefPubMedGoogle Scholar
  • 27 Chu JYS, Lee LTO, Lai CH, Vaudry H, Chan YS, Yung WH, Chow BKC. Secretin as a neurohypophysial factor regulating body water homeostasis. Proc Natl Acad Sci USA 2009; 106: 15961-15966
    CrossrefPubMedGoogle Scholar
  • 28 Chu J, Yung W, Chow B. Secretin: a pleiotrophic hormone. Ann N Y Acad Sci 2006; 1070: 27-50
    CrossrefPubMedGoogle Scholar
  • 29 O’Donohue TL, Charlton CG, Miller RL, Boden G, Jacobowitz DM. Identification, characterization, and distribution of secretin immunoreactivity in rat and pig brain. Proc Natl Acad Sci USA 1981; 78: 5221-5224
    CrossrefPubMedGoogle Scholar
  • 30 Samson WK, Lumpkin MD, McCann SM. Presence and possible site of action of secretin in the rat pituitary and hypothalamus. Life Sci 1984; 34: 155-163
    CrossrefPubMedGoogle Scholar
  • 31 Charlton CG, O’Donohue TL, Miller RL, Jacobowitz DM. Secretin immunoreactivity in rat and pig brain. Peptides 1981; 2 (Suppl. 01) 45-49
    PubMedGoogle Scholar
  • 32 Welch MG, Keune JD, Welch-Horan TB, Anwar N, Anwar M, Ludwig RJ, Ruggiero DA. Secretin: hypothalamic distribution and hypothesized neuroregulatory role in autism. Cell Mol Neurobiol 2004; 24: 219-241
    CrossrefPubMedGoogle Scholar
  • 33 Tay J, Goulet M, Rusche J, Boismenu R. Age-related and regional differences in secretin and secretin receptor mRNA levels in the rat brain. Neurosci Lett 2004; 366: 176-181
    CrossrefPubMedGoogle Scholar
  • 34 Cheng CYY, Chu JYS, Chow BKC. Central and Peripheral Administration of Secretin Inhibits Food Intake in Mice through the Activation of the Melanocortin System. Neuropsychopharmacology 2011; 36: 459-471
    CrossrefPubMedGoogle Scholar
  • 35 Glick Z, Thomas DW, Mayer J. Absence of effect of injections of the intestinal hormones secretin and cholecystokinin-pancreozymin upon feeding behavior. Physiol Behav 1971; 6: 5-8
    CrossrefPubMedGoogle Scholar
  • 36 Gibbs J, Young RC, Smith GP. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 1973; 84: 488-495
    CrossrefPubMedGoogle Scholar
  • 37 Lorenz DN, Kreielsheimer G, Smith GP. Effect of cholecystokinin, gastrin, secretin and GIP on sham feeding in the rat. Physiol Behav 1979; 23: 1065-1072
    CrossrefPubMedGoogle Scholar
  • 38 Yang H, Wang L, Wu SV, Tay J, Goulet M, Boismenu R, Czimmer J, Wang Y, Wu S, Ao Y, Taché Y. Peripheral secretin-induced Fos expression in the rat brain is largely vagal dependent. Neuroscience 2004; 128: 131-141
    CrossrefPubMedGoogle Scholar
  • 39 Chu JY, Cheng CY, Sekar R, Chow BK. Vagal Afferent Mediates the Anorectic Effect of Peripheral Secretin. PloS One 2013; 8: e64859
    CrossrefPubMedGoogle Scholar
  • 40 Banks WA, Goulet M, Rusche JR, Niehoff ML, Boismenu R. Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse. J Pharmacol Exp Therap 2002; 302: 1062-1069
    CrossrefPubMedGoogle Scholar
  • 41 Li Y, Wu X, Yao H, Owyang C. Secretin activates vagal primary afferent neurons in the rat: evidence from electrophysiological and immunohistochemical studies. Am J Physiol Gastrointest Liver Physiol 2005; 289: G745-G752
    PubMedGoogle Scholar
  • 42 Sekar R, Chow BKC. Metabolic effects of secretin. Gen Comp Endocrinol 2013; 181: 18-24
    CrossrefPubMedGoogle Scholar
  • 43 Chu JY, Yung WH, Chow BK. Endogenous release of secretin from the hypothalamus. Ann N Y Acad Sci 2006; 1070: 196-200
    CrossrefPubMedGoogle Scholar
  • 44 Heppner KM, Habegger KM, Day J, Pfluger PT, Perez-Tilve D, Ward B, Gelfanov V, Woods SC, DiMarchi R, Tschöp M. Glucagon regulation of energy metabolism. Physiol Behav 2010; 100: 545-548
    CrossrefPubMedGoogle Scholar
  • 45 Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010; 6: 689-697
    CrossrefPubMedGoogle Scholar
  • 46 Jones BJ, Tan T, Bloom SR. Minireview: Glucagon in Stress and Energy Homeostasis. Endocrinology 2012; 153: 1049-1054
    CrossrefPubMedGoogle Scholar
  • 47 Penick SB, Hinkle Jr LE. Depression of food intake induced in healthy subjects by glucagon. N Engl J Med 1961; 264: 893-897
    CrossrefPubMedGoogle Scholar
  • 48 Martin JR, Novin D. Decreased feeding in rats following hepatic-portal infusion of glucagon. Physiol Behav 1977; 19: 461-466
    CrossrefPubMedGoogle Scholar
  • 49 Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol Regul Integ Comp Physiol 1992; 262: R975-R980
    PubMedGoogle Scholar
  • 50 Geary N, Smith GP. Selective hepatic vagotomy blocks pancreatic glucagon’s satiety effect. Physiol Behav 1983; 31: 391-394
    CrossrefPubMedGoogle Scholar
  • 51 Morawska D, Sieklucka-Dziuba M, Kleinrok Z. Central action of glucagon. Pol J Pharmacol 1998; 50: 125-133
    PubMedGoogle Scholar
  • 52 Honda K, Kamisoyama H, Uemura T, Yanagi T, Saito N, Kurose Y, Sugahara K, Katoh K, Hasegawa S. The mechanism underlying the central glucagon-induced hyperglycemia and anorexia in chicks. Comp Biochem Physiol A Mol Integ Physiol 2012; 163: 260-264
    CrossrefPubMedGoogle Scholar
  • 53 Kurose Y, Kamisoyama H, Honda K, Azuma Y, Sugahara K, Hasegawa S, Kobayashi S. Effects of central administration of glucagon on feed intake and endocrine responses in sheep. Anim Sci J 2009; 80: 686-690
    CrossrefPubMedGoogle Scholar
  • 54 Shimizu H, Egawa M, Yoshimatsu H, Bray GA. Glucagon injected in the lateral hypothalamus stimulates sympathetic activity and suppresses monoamine metabolism. Brain Res 1993; 630: 95-100
    CrossrefPubMedGoogle Scholar
  • 55 Inokuchi A, Oomura Y, Shimizu N, Yamamoto T. Central action of glucagon in rat hypothalamus. Am J Physiol Regul Integ Comp Physiol 1986; 250: R120-R126
    PubMedGoogle Scholar
  • 56 Hoosein NM, Gurd RS. Identification of glucagon receptors in rat brain. Proc Natl Acad Sci 1984; 81: 4368-4372
    CrossrefPubMedGoogle Scholar
  • 57 Parker JA, McCullough KA, Field BC, Minnion JS, Martin NM, Ghatei MA, Bloom SR. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int J Obes (Lond) 2013; DOI: 10.1038/ijo.2012.227. [Epub ahead of print]
    PubMedGoogle Scholar
  • 58 Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132: 2131-2157
    CrossrefPubMedGoogle Scholar
  • 59 Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 1409-1439
    CrossrefPubMedGoogle Scholar
  • 60 Kreymann B, Ghatei M, Williams G, Bloom S. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 330: 1300-1304
    CrossrefPubMedGoogle Scholar
  • 61 Barrera JG, Sandoval DA, D’Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011; 7: 507-516
    CrossrefPubMedGoogle Scholar
  • 62 Hayes MR. Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects. Physiol Behav 2012; 106: 413-416
    CrossrefPubMedGoogle Scholar
  • 63 Hayes MR, De Jonghe BC, Kanoski SE. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiol Behav 2010; 100: 503-510
    CrossrefPubMedGoogle Scholar
  • 64 Meier JJ, Gallwitz B, Schmidt WE, Nauck MA. Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 2002; 440: 269-279
    CrossrefPubMedGoogle Scholar
  • 65 Punjabi M, Arnold M, Geary N, Langhans W, Pacheco-López G. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiol Behav 2011; 105: 71-76
    CrossrefPubMedGoogle Scholar
  • 66 Hayes MR, Kanoski SE, De Jonghe BC, Leichner TM, Alhadeff AL, Fortin SM, Arnold M, Langhans W, Grill HJ. The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1. Am J Physiol Regul Integ Comp Physiol 2011; 301: R1479-R1485
    CrossrefPubMedGoogle Scholar
  • 67 Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol Endocrinol Metabol 1996; 271: E808-E813
    PubMedGoogle Scholar
  • 68 Hayes MR, Bradley L, Grill HJ. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009; 150: 2654-2659
    CrossrefPubMedGoogle Scholar
  • 69 Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and Central GLP-1 Receptor Populations Mediate the Anorectic Effects of Peripherally Administered GLP-1 Receptor Agonists, Liraglutide and Exendin-4. Endocrinology 2011; 152: 3103-3112
    CrossrefPubMedGoogle Scholar
  • 70 Turton M, O’shea D, Gunn I, Beak S, Edwards C, Meeran K, Choi S, Taylor G, Heath M, Lambert P. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379: 69-72
    CrossrefPubMedGoogle Scholar
  • 71 Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR. Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 2005; 115: 3554-3563
    CrossrefPubMedGoogle Scholar
  • 72 Williams DL. Minireview: Finding the Sweet Spot: Peripheral Versus Central Glucagon-Like Peptide 1 Action in Feeding and Glucose Homeostasis. Endocrinology 2009; 150: 2997-3001
    CrossrefPubMedGoogle Scholar
  • 73 Sandoval DA, Bagnol D, Woods SC, D’Alessio DA, Seeley RJ. Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake. Diabetes 2008; 57: 2046-2054
    CrossrefPubMedGoogle Scholar
  • 74 Tang-Christensen M, Larsen P, Goke R, Fink-Jensen A, Jessop D, Moller M, Sheikh S. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol Regul Integ Comp Physiol 1996; 271: R848-R856
    PubMedGoogle Scholar
  • 75 Thiele TE, Van Dijk G, Campfield LA, Smith FJ, Burn P, Woods SC, Bernstein IL, Seeley RJ. Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol Regul Integ Comp Physiol 1997; 272: R726-R730
    PubMedGoogle Scholar
  • 76 McMahon LR, Wellman PJ. PVN infusion of GLP-1-(7–36) amide suppresses feeding but does not induce aversion or alter locomotion in rats. Am J Physiol Regul Integ Comp Physiol 1998; 274: R23-R29
    PubMedGoogle Scholar
  • 77 Kinzig KP, D’Alessio DA, Seeley RJ. The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. J Neurosci 2002; 22: 10470-10476
    PubMedGoogle Scholar
  • 78 Kinzig KP, D’Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, Murphy EK, Seeley RJ. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003; 23: 6163-6170
    PubMedGoogle Scholar
  • 79 Challa TD, Beaton N, Arnold M, Rudofsky G, Langhans W, Wolfrum C. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem 2012; 287: 6421-6430
    CrossrefPubMedGoogle Scholar
  • 80 Hayes MR, Skibicka KP, Grill HJ. Caudal Brainstem Processing Is Sufficient for Behavioral, Sympathetic, and Parasympathetic Responses Driven by Peripheral and Hindbrain Glucagon-Like-Peptide-1 Receptor Stimulation. Endocrinology 2008; 149: 4059-4068
    CrossrefPubMedGoogle Scholar
  • 81 Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake. Endocrinology 2012; 153: 647-658
    CrossrefPubMedGoogle Scholar
  • 82 Dossat AM, Lilly N, Kay K, Williams DL. Glucagon-Like Peptide 1 Receptors in Nucleus Accumbens Affect Food Intake. J Neurosci 2011; 31: 14453-14457
    CrossrefPubMedGoogle Scholar
  • 83 Goldstone AP, Mercer JG, Gunn I, Moar KM, Edwards CMB, Rossi M, Howard JK, Rasheed S, Turton MD, Small C. Leptin interacts with glucagon-like peptide-1 neurons to reduce food intake and body weight in rodents. FEBS Lett 1997; 415: 134-138
    CrossrefPubMedGoogle Scholar
  • 84 Scrocchi LA, Drucker DJ. Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor−/− mice. Endocrinology 1998; 139: 3127-3132
    CrossrefPubMedGoogle Scholar
  • 85 Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47
    CrossrefPubMedGoogle Scholar
  • 86 Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635
    CrossrefPubMedGoogle Scholar
  • 87 Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091
    CrossrefPubMedGoogle Scholar
  • 88 Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616
    CrossrefPubMedGoogle Scholar
  • 89 Morínigo R, Lacy AM. GLP-1 and changes in glucose tolerance following gastric bypass surgery in morbidly obese subjects. Obes Surg 2006; 16: 1594-1601
    CrossrefPubMedGoogle Scholar
  • 90 Emeric-Sauval E. Corticotropin-releasing factor (CRF) – a review. Psychoneuroendocrinology 1986; 11: 277-294
    CrossrefPubMedGoogle Scholar
  • 91 Rivier CL, Plotsky PM. Mediation by corticotropin releasing factor (CRF) of adenohypophysial hormone secretion. Ann Rev Physiol 1986; 48: 475-494
    CrossrefPubMedGoogle Scholar
  • 92 Liposits Z, Phelix C, Paull W. Synaptic interaction of serotonergic axons and corticotropin releasing factor (CRF) synthesizing neurons in the hypothalamic paraventricular nucleus of the rat. Histochemistry 1987; 86: 541-549
    CrossrefPubMedGoogle Scholar
  • 93 Dunn AJ, Berridge CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses. Brain Res Rev 1990; 15: 100
    PubMedGoogle Scholar
  • 94 Turnbull AV, Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. In: Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine. New York, NY: Royal Society of Medicine; 1997: 1-10
    Google Scholar
  • 95 Rothwell NJ. Central effects of CRF on metabolism and energy balance. Neurosci Biobehav Rev 1990; 14: 263-271
    CrossrefPubMedGoogle Scholar
  • 96 Owens MJ, Nemeroff CB. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev 1991; 43: 425-473
    PubMedGoogle Scholar
  • 97 Tanaka C, Asakawa A, Ushikai M, Sakoguchi T, Amitani H, Terashi M, Cheng K, Chaolu H, Nakamura N, Inui A. Comparison of the anorexigenic activity of CRF family peptides. Biochem Biophy Res Commun 2009; 390: 887-891
    CrossrefPubMedGoogle Scholar
  • 98 Richard D, Lin Q, Timofeeva E. The corticotropin-releasing factor family of peptides and CRF receptors: their roles in the regulation of energy balance. Eur J Pharmacol 2002; 440: 189-197
    CrossrefPubMedGoogle Scholar
  • 99 Smith GW, Aubry J-M, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee K-F. Corticotropin Releasing Factor Receptor 1-Deficient Mice Display Decreased Anxiety, Impaired Stress Response, and Aberrant Neuroendocrine Development. Neuron 1998; 20: 1093-1102
    CrossrefPubMedGoogle Scholar
  • 100 Doyon C, Samson P, Lalonde J, Richard D. Effects of the CRF1 receptor antagonist SSR125543 on energy balance and food deprivation-induced neuronal activation in obese Zucker rats. J Endocrinol 2007; 193: 11-19
    CrossrefPubMedGoogle Scholar
  • 101 Chao H, Digruccio M, Chen P, Li C. Type 2 Corticotropin-Releasing Factor Receptor in the Ventromedial Nucleus of Hypothalamus Is Critical in Regulating Feeding and Lipid Metabolism in White Adipose Tissue. Endocrinology 2012; 153: 166-176
    CrossrefPubMedGoogle Scholar
  • 102 Chen P, Van Hover C, Lindberg D, Li C. Central urocortin 3 and type 2 corticotropin-releasing factor receptor in the regulation of energy homeostasis: critical involvement of the ventromedial hypothalamus. Front Endocrinol (Lausanne) 2012; 3: 180, DOI: 10.3389/fendo.2012.00180. [Epub 2013 Jan 7]
    PubMedGoogle Scholar
  • 103 Carlin KM, Vale WW, Bale TL. Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 2006; 103: 3462-3467
    CrossrefPubMedGoogle Scholar
  • 104 Bradbury MJ, McBurnie MI, Denton DA, Lee K-F, Vale WW. Modulation of urocortin-induced hypophagia and weight loss by corticotropin-releasing factor receptor 1 deficiency in mice. Endocrinology 2000; 141: 2715-2724
    CrossrefPubMedGoogle Scholar
  • 105 Coste SC, Kesterson RA, Heldwein KA, Stevens SL, Heard AD, Hollis JH, Murray SE, Hill JK, Pantely GA, Hohimer AR. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Gen 2000; 24: 403-409
    CrossrefPubMedGoogle Scholar
  • 106 Lu X-Y, Barsh GS, Akil H, Watson SJ. Interaction between α-Melanocyte-Stimulating Hormone and Corticotropin-Releasing Hormone in the Regulation of Feeding and Hypothalamo-Pituitary-Adrenal Responses. J Neurosci 2003; 23: 7863-7872
    PubMedGoogle Scholar
  • 107 Kawashima S, Sakihara S, Kageyama K, Nigawara T, Suda T. Corticotropin-releasing factor (CRF) is involved in the acute anorexic effect of a-melanocyte-stimulating hormone: A study using CRF-deficient mice. Peptides 2008; 29: 2169-2174
    CrossrefPubMedGoogle Scholar
  • 108 Heilig M, Koob GF. A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 2007; 30: 399-406
    CrossrefPubMedGoogle Scholar
  • 109 Bogdan R, Santesso DL, Fagerness J, Perlis RH, Pizzagalli DA. Corticotropin-releasing hormone receptor type 1 (CRHR1) genetic variation and stress interact to influence reward learning. J Neurosci 2011; 31: 13246-13254
    CrossrefPubMedGoogle Scholar
  • 110 Cottone P, Sabino V, Roberto M, Bajo M, Pockros L, Frihauf JB, Fekete EM, Steardo L, Rice KC, Grigoriadis DE. CRF system recruitment mediates dark side of compulsive eating. Proc Natl Acad Sci USA 2009; 106: 20016-20020
    CrossrefPubMedGoogle Scholar
  • 111 Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-574
    CrossrefPubMedGoogle Scholar
  • 112 Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: From Structure to Functions. Pharmacol Rev 2000; 52: 269-324
    PubMedGoogle Scholar
  • 113 Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BKC, Hashimoto H, Galas L, Vaudry H. Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery. Pharmacol Rev 2009; 61: 283-357
    CrossrefPubMedGoogle Scholar
  • 114 Koves K, Arimura A, Gorcs TG, Somogyvari-Vigh A. Comparative distribution of immunoreactive pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide in rat forebrain. Neuroendocrinology 1991; 54: 159-169
    CrossrefPubMedGoogle Scholar
  • 115 Morley JE, Horowitz M, Morley PM, Flood JF. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces food intake in mice. Peptides 1992; 13: 1133-1135
    CrossrefPubMedGoogle Scholar
  • 116 Dürr K, Norsted E, Gömüç B, Suarez E, Hannibal J, Meister B. Presence of pituitary adenylate cyclase-activating polypeptide (PACAP) defines a subpopulation of hypothalamic POMC neurons. Brain Res 2007; 1186: 203-211
    CrossrefPubMedGoogle Scholar
  • 117 Mounien L, Bizet P, Boutelet I, Gourcerol G, Fournier A, Vaudry H, Jégou S. Pituitary adenylate cyclase-activating polypeptide directly modulates the activity of proopiomelanocortin neurons in the rat arcuate nucleus. Neuroscience 2006; 143: 155-163
    CrossrefPubMedGoogle Scholar
  • 118 Mounien L, Bizet P, Boutelet I, Gourcerol G, Basille M, Gonzalez B, Vaudry H, Jegou S. Expression of PACAP Receptor mRNAs by Neuropeptide Y Neurons in the Rat Arcuate Nucleus. Ann N Y Acad Sci 2006; 1070: 457-461
    CrossrefPubMedGoogle Scholar
  • 119 Nakata M, Kohno D, Shintani N, Nemoto Y, Hashimoto H, Baba A, Yada T. PACAP deficient mice display reduced carbohydrate intake and PACAP activates NPY-containing neurons in the rat hypothalamic arcuate nucleus. Neurosci Lett 2004; 370: 252-256
    CrossrefPubMedGoogle Scholar
  • 120 Mounien L, Do Rego JC, Bizet P, Boutelet I, Gourcerol G, Fournier A, Brabet P, Costentin J, Vaudry H, Jegou S. Pituitary adenylate cyclase-activating polypeptide inhibits food intake in mice through activation of the hypothalamic melanocortin system. Neuropsychopharmacology 2009; 34: 424-435
    CrossrefPubMedGoogle Scholar
  • 121 Resch JM, Boisvert JP, Hourigan AE, Mueller CR, Yi SS, Choi S. Stimulation of the hypothalamic ventromedial nuclei by pituitary adenylate cyclase-activating polypeptide induces hypophagia and thermogenesis. Am J Physiol Regul Integ Comp Physiol 2011; 301: R1625-R1634
    CrossrefPubMedGoogle Scholar
  • 122 Hawke Z, Ivanov TR, Bechtold DA, Dhillon H, Lowell BB, Luckman SM. PACAP Neurons in the Hypothalamic Ventromedial Nucleus Are Targets of Central Leptin Signaling. J Neurosci 2009; 29: 14828-14835
    CrossrefPubMedGoogle Scholar
  • 123 Adams BA, Gray SL, Isaac ER, Bianco AC, Vidal-Puig AJ, Sherwood NM. Feeding and Metabolism in Mice Lacking Pituitary Adenylate Cyclase-Activating Polypeptide. Endocrinology 2008; 149: 1571-1580
    CrossrefPubMedGoogle Scholar
  • 124 Sherwood NM, Adams BA, Isaac ER, Wu S, Fradinger EA. Knocked down and out: PACAP in development, reproduction and feeding. Peptides 2007; 28: 1680-1687
    CrossrefPubMedGoogle Scholar
  • 125 Yi C-X, Sun N, Ackermans MT, Alkemade A, Foppen E, Shi J, Serlie MJ, Buijs RM, Fliers E, Kalsbeek A. Pituitary Adenylate Cyclase-Activating Polypeptide Stimulates Glucose Production via the Hepatic Sympathetic Innervation in Rats. Diabetes 2010; 59: 1591-1600
    CrossrefPubMedGoogle Scholar
  • 126 Said SI, Mutt V. Isolation from Porcine-Intestinal Wall of a Vasoactive Octacosapeptide Related to Secretin and to Glucagon. Eur J Biochem 1972; 28: 199-204
    CrossrefPubMedGoogle Scholar
  • 127 Fuxe K, Hökfelt T, Said SI, Mutt V. Vasoactive intestinal polypeptide and the nervous system: Immunohistochemical evidence for localization in central and peripheral neurons, particularly intracortical neurons of the cerebral cortex. Neurosci Lett 1977; 5: 241-246
    CrossrefPubMedGoogle Scholar
  • 128 Dussaillant M, Sarrieau A, Gozes I, Berod A, Rostene W. Distribution of cells expressing vasoactive intestinal peptide/peptide histidine isoleucine-amide precursor messenger rna in the rat brain. Neuroscience 1992; 50: 519-530
    CrossrefPubMedGoogle Scholar
  • 129 Usdin TB, Bonner TI, Mezey E. Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 1994; 135: 2662-2680
    CrossrefPubMedGoogle Scholar
  • 130 Alexander LD, Sander LD. Vasoactive intestinal peptide stimulates ACTH and corticosterone release after injection into the PVN. Regul Pept 1994; 51: 221-227
    CrossrefPubMedGoogle Scholar
  • 131 Alexander LD, Sander LD. Involvement of vasopressin and corticotropin-releasing hormone in VIP- and PHI-induced secretion of ACTH and corticosterone. Neuropeptides 1995; 28: 167-173
    CrossrefPubMedGoogle Scholar
  • 132 Tachibana T, Saito S, Tomonaga S, Takagi T, Saito E-S, Boswell T, Furuse M. Intracerebroventricular injection of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibits feeding in chicks. Neurosci Lett 2003; 339: 203-206
    CrossrefPubMedGoogle Scholar
  • 133 Matsuda K, Maruyama K, Nakamachi T, Miura T, Uchiyama M, Shioda S. Inhibitory effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) on food intake in the goldfish, Carassius auratus. Peptides 2005; 26: 1611-1616
    CrossrefPubMedGoogle Scholar
  • 134 Ghourab S, Beale KE, Semjonous NM, Simpson KA, Martin NM, Ghatei MA, Bloom SR, Smith KL. Intracerebroventricular administration of vasoactive intestinal peptide inhibits food intake. Regul Pept 2011; 172: 8-15
    CrossrefPubMedGoogle Scholar
  • 135 Jozsa R, Nemeth J, Tamas A, Hollosy T, Lubics A, Jakab B, Olah A, Lengvari I, Arimura A, Reglödi D. Short-Term Fasting Differentially Alters PACAP and VIP Levels in the Brains of Rat and Chicken. Ann N Y Acad Sci 2006; 1070: 354-358
    CrossrefPubMedGoogle Scholar
  • 136 Bechtold DA, Brown TM, Luckman SM, Piggins HD. Metabolic rhythm abnormalities in mice lacking VIP-VPAC2 signaling. Am J Physiol Regul Integ Comp Physiol 2008; 294: R344-R351
    PubMedGoogle Scholar
  • 137 Alexander LD, Evans K, Sander LD. A possible involvement of VIP in feeding-induced secretion of ACTH and corticosterone in the Rat. Physiol Behav 1995; 58: 409-413
    CrossrefPubMedGoogle Scholar
  • 138 Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB, Guillemin R. Growth hormone-releasing factor from ovine and caprine hypothalamus: Isolation, sequence analysis and total synthesis. Biochem Biophys Res Commun 1984; 125: 606-614
    CrossrefPubMedGoogle Scholar
  • 139 Krulich L, Dhariwal APS, Mccann SM. Stimulatory and Inhibitory Effects of Purified Hypothalamic Extracts on Growth Hormone Release from Rat Pituitary in Vitro. Endocrinology 1968; 83: 783-790
    CrossrefPubMedGoogle Scholar
  • 140 Esch F, Böhlen P, Ling N, Brazeau P, Guillemin R. Isolation and characterization of the bovine hypothalamic growth hormone releasing factor. Biochem Biophys Res Commun 1983; 117: 772-779
    CrossrefPubMedGoogle Scholar
  • 141 VandePol CJ, Leidy Jr JW, Finger TE, Robbins RJ. Immunohistochemical localization of GRF-containing neurons in rat brain. Neuroendocrinology 1986; 42: 143-147
    CrossrefPubMedGoogle Scholar
  • 142 Vaccarino FJ, Feifel D, Rivier J, Vale W, Koob GF. Centrally administered hypothalamic growth hormone-releasing factor stimulates food intake in free-feeding rats. Peptides 1988; 9 (Suppl. 01) 35-38
    CrossrefPubMedGoogle Scholar
  • 143 Vaccarino FJ, Bloom FE, Rivier J, Vale W, Koob GF. Stimulation of food intake in rats by centrally administered hypothalamic growth hormone-releasing factor. Nature 1985; 314: 167-168
    CrossrefPubMedGoogle Scholar
  • 144 Sawchenko PE, Swanson LW, Rivier J, Vale WW. The distribution of growth-hormone-releasing factor (GRF) immunoreactivity in the central nervous system of the rat: an immunohistochemical study using antisera directed against rat hypothalamic GRF. J Comp Neurol 1985; 237: 100-115
    CrossrefPubMedGoogle Scholar
  • 145 Vaccarino FJ, Hayward M. Microinjections of growth hormone-releasing factor into the medial preoptic area/suprachiasmatic nucleus region of the hypothalamus stimulate food intake in rats. Regul Pept 1988; 21: 21-28
    CrossrefPubMedGoogle Scholar
  • 146 Dickson PR, Vaccarino FJ. Characterization of feeding behavior induced by central injection of GRF. Am J Physiol Regul Integ Comp Physiol 1990; 259: R651-R657
    PubMedGoogle Scholar
  • 147 Dickson PR, Vaccarino FJ. GRF-induced feeding: Evidence for protein selectivity and opiate involvement. Peptides 1994; 15: 1343-1352
    CrossrefPubMedGoogle Scholar
  • 148 Vaccarino FJ, Buckenham KE. Naloxone blockade of growth hormone-releasing factor-induced feeding. Regul Pept 1987; 18: 165-171
    CrossrefPubMedGoogle Scholar
  • 149 Vaccarino FJ, Taube MR. Intra-Arcuate Opiate Actions Stimulate GRF-Dependent and Protein-Selective Feeding. Peptides 1997; 18: 197-205
    CrossrefPubMedGoogle Scholar
  • 150 Rusak B, Zucker I. Neural regulation of circadian rhythms. Physiol Rev 1979; 59: 449-526
    PubMedGoogle Scholar
  • 151 Feifel D, Vaccarino FJ. Feeding effects of growth hormone-releasing factor in rats are photoperiod sensitive. Behav Neurosci 1989; 103: 824-830
    CrossrefPubMedGoogle Scholar
  • 152 Vaccarino F, Feifel D, Rivier J, Vale W. Antagonism of central growth hormone-releasing factor activity selectively attenuates dark-onset feeding in rats. J Neurosci 1991; 11: 3924-3927
    PubMedGoogle Scholar
  • 153 Dickson PR, Feifel D, Vaccarino FJ. Blockade of endogenous GRF at dark onset selectively suppresses protein intake. Peptides 1995; 16: 7-9
    CrossrefPubMedGoogle Scholar
  • 154 Feifel D, Vaccarino FJ. Growth hormone-regulatory peptides (GHRH and somatostatin) and feeding: A model for the integration of central and peripheral function. Neurosci Biobehav Rev 1994; 18: 421-433
    CrossrefPubMedGoogle Scholar
  • 155 Roh J, Chang CL, Bhalla A, Klein C, Hsu SYT. Intermedin Is a Calcitonin/Calcitonin Gene-related Peptide Family Peptide Acting through the Calcitonin Receptor-like Receptor/Receptor Activity-modifying Protein Receptor Complexes. J Biol Chem 2004; 279: 7264-7274
    PubMedGoogle Scholar
  • 156 Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W, Muff R, Fischer JA, Foord SM. International Union of Pharmacology. XXXII. The Mammalian Calcitonin Gene-Related Peptides, Adrenomedullin, Amylin, and Calcitonin Receptors. Pharmacol Rev 2002; 54: 233-246
    CrossrefPubMedGoogle Scholar
  • 157 Lutz TA, Rossi R, Althaus J, Del Prete E, Scharrer E. Amylin reduces food intake more potently than calcitonin gene-related peptide (CGRP) when injected into the lateral brain ventricle in rats. Peptides 1998; 19: 1533-1540
    CrossrefPubMedGoogle Scholar
  • 158 Flynn JJ, Margules DL, Cooper CW. Presence of immunoreactive calcitonin in the hypothalamus and pituitary lobes of rats. Brain Res Bull 1981; 6: 547-549
    CrossrefPubMedGoogle Scholar
  • 159 Yamamoto Y, Nakamuta H, Koida M, Seyler JK, Orlowski RC. Calcitonin-induced anorexia in rats: a structure-activity study by intraventricular injections. Jap J Pharmacol 1982; 32: 1013
    CrossrefPubMedGoogle Scholar
  • 160 Perlow MJ, Freed WJ, Carman JS, Wyatt RJ. Calcitonin reduces feeding in man, monkey and rat. Pharmacol Biochem Behav 1980; 12: 609-612
    CrossrefPubMedGoogle Scholar
  • 161 Gaggi R, Beltrandi E, Dall’Olio R, Ferri S. Relationships between hypocalcaemic and anorectic effect of calcitonin in the rat. Pharmacol Res Commun 1985; 17: 209-215
    CrossrefPubMedGoogle Scholar
  • 162 de Beaurepaire R, Freed WJ. Anatomical mapping of the rat hypothalamus for calcitonin-induced anorexia. Pharmacol Biochem Behav 1987; 27: 177-182
    CrossrefPubMedGoogle Scholar
  • 163 Chelikani PK, Haver AC, Reidelberger RD. Effects of intermittent intraperitoneal infusion of salmon calcitonin on food intake and adiposity in obese rats. Am J Physiol Regul Integ Comp Physiol 2007; 293: R1798-R1808
    CrossrefPubMedGoogle Scholar
  • 164 Morley JE, Levine AS, Brown DM, Handwerger BS. The effect of calcitonin on food intake in diabetic mice. Peptides 1982; 3: 17-20
    CrossrefPubMedGoogle Scholar
  • 165 Eiden S, Daniel C, Steinbrueck A, Schmidt I, Simon E. Salmon calcitonin – a potent inhibitor of food intake in states of impaired leptin signalling in laboratory rodents. J Physiol 2002; 541: 1041-1048
    CrossrefPubMedGoogle Scholar
  • 166 Bello NT, Kemm MH, Moran TH. Salmon calcitonin reduces food intake through changes in meal sizes in male rhesus monkeys. Am J Physiol Regul Integ Comp Physiol 2008; 295: R76-R81
    CrossrefPubMedGoogle Scholar
  • 167 Zhang Z, Liu X, Morgan DA, Kuburas A, Thedens DR, Russo AF, Rahmouni K. Neuronal Receptor Activity-Modifying Protein 1 Promotes Energy Expenditure in Mice. Diabetes 2011; 60: 1063-1071
    CrossrefPubMedGoogle Scholar
  • 168 Dhillo WS, Small CJ, Jethwa PH, Russell SH, Gardiner JV, Bewick GA, Seth A, Murphy KG, Ghatei MA, Bloom SR. Paraventricular Nucleus Administration of Calcitonin Gene-Related Peptide Inhibits Food Intake and Stimulates the Hypothalamo-Pituitary-Adrenal Axis. Endocrinology 2003; 144: 1420-1425
    CrossrefPubMedGoogle Scholar
  • 169 Sun JY, Jing MY, Wang JF, Weng XY. Original Article: The approach to the mechanism of calcitonin gene-related peptide-inducing inhibition of food intake. J Anim Physiol Anim Nutr 2010; 94: 552-560
    CrossrefPubMedGoogle Scholar
  • 170 Taylor GM, Meeran K, O’Shea D, Smith DM, Ghatei MA, Bloom SR. Adrenomedullin inhibits feeding in the rat by a mechanism involving calcitonin gene-related peptide receptors. Endocrinology 1996; 137: 3260-3264
    CrossrefPubMedGoogle Scholar
  • 171 Taylor MM, Bagley SL, Samson WK. Intermedin/adrenomedullin-2 acts within central nervous system to elevate blood pressure and inhibit food and water intake. Am J Physiol Regul Integ Comp Physiol 2005; 288: R919-R927
    PubMedGoogle Scholar
  • 172 Sawada H, Yamaguchi H, Shimbara T, Toshinai K, Mondal MS, Date Y, Murakami N, Katafuchi T, Minamino N, Nunoi H, Nakazato M. Central Effects of Calcitonin Receptor-Stimulating Peptide-1 on Energy Homeostasis in Rats. Endocrinology 2006; 147: 2043-2050
    CrossrefPubMedGoogle Scholar
  • 173 Lutz TA. Amylinergic control of food intake. Physiol Behav 2006; 89: 465-471
    CrossrefPubMedGoogle Scholar
  • 174 Rushing PA. Central amylin signaling and the regulation of energy homeostasis. Curr Pharmaceut Des 2003; 9: 819-825
    CrossrefPubMedGoogle Scholar
  • 175 Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integ Comp Physiol 2010; 298: R1475-R1484
    CrossrefPubMedGoogle Scholar
  • 176 Lutz T. Control of energy homeostasis by amylin. Cell Mol Life Sci 2012; 69: 1947-1965
    CrossrefPubMedGoogle Scholar
  • 177 Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philos Trans R Soc Lond B Biol Sci 2006; 361: 1219-1235
    PubMedGoogle Scholar
  • 178 Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes DG, Baron AD. Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies. Proc Natl Acad Sci USA 2008; 105: 7257-7262
    CrossrefPubMedGoogle Scholar
  • 179 Turek VF, Trevaskis JL, Levin BE, Dunn-Meynell AA, Irani B, Gu G, Wittmer C, Griffin PS, Vu C, Parkes DG. Mechanisms of amylin/leptin synergy in rodent models. Endocrinology 2010; 151: 143-152
    CrossrefPubMedGoogle Scholar
  • 180 Mack C, Soares C, Wilson J, Athanacio J, Turek V, Trevaskis J, Roth J, Smith P, Gedulin B, Jodka C. Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight. Inter J Obes 2009; 34: 385-395
    PubMedGoogle Scholar
  • 181 Guan X, Shi X, Li X, Chang B, Wang Y, Li D-P, Chan L. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. Am J Physiol Endocrinol Metab 2012; 303: E853-E864
    CrossrefPubMedGoogle Scholar
  • 182 Tang-Christensen M, Larsen PJ, Thulesen J, Rømer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6: 802-807
    CrossrefPubMedGoogle Scholar
  • 183 Dalvi PS, Belsham DD. Glucagon-Like Peptide-2 Directly Regulates Hypothalamic Neurons Expressing Neuropeptides Linked to Appetite Control in Vivo and in Vitro. Endocrinology 2012; 153: 2385-2397
    CrossrefPubMedGoogle Scholar
  • 184 Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001; 276: 21489-21499
    CrossrefPubMedGoogle Scholar
  • 185 Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742
    CrossrefPubMedGoogle Scholar
  • 186 Woods S, West D, Stein LJ, McKay L, Lotter EC, Porte SG, Kenney NJ, Porte Jr D. Peptides and the control of meal size. Diabetologia 1981; 20: 305-313
    CrossrefPubMedGoogle Scholar
  • 187 Gault V, McClean P, Cassidy R, Irwin N, Flatt P. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007; 50: 1752-1762
    CrossrefPubMedGoogle Scholar
  • 188 Ambati S, Duan J, Hartzell DL, Choi Y-H, Della-Fera MA, Baile CA. GIP-dependent expression of hypothalamic genes. Physiol Res/Acad Sci Bohem 2011; 60: 941-950
    PubMedGoogle Scholar
  • 189 Epstein FH, Strewler GJ. The physiology of parathyroid hormone–related protein. N Engl J Med 2000; 342: 177-185
    CrossrefPubMedGoogle Scholar
  • 190 Asakawa A, Fujimiya M, Niijima A, Fujino K, Kodama N, Sato Y, Kato I, Nanba H, Laviano A, Meguid MM. Parathyroid hormone-related protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology 2010; 35: 1178-1186
    CrossrefPubMedGoogle Scholar
  • 191 Burtis WJ, Brady TG, Orloff JJ, Ersbak JB, Warrell Jr RP, Olson BR, Wu TL, Mitnick ME, Broadus AE, Stewart AF. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 1990; 322: 1106-1112
    CrossrefPubMedGoogle Scholar
  • 192 McCarty M, Thomas C. PTH excess may promote weight gain by impeding catecholamine-induced lipolysis – implications for the impact of calcium, vitamin D, and alcohol on body weight. Med Hypoth 2003; 61: 535-542
    CrossrefPubMedGoogle Scholar